Axsome Therapeutics (NASDAQ:AXSM) Issues Quarterly Earnings Results

Axsome Therapeutics (NASDAQ:AXSM - Get Free Report) issued its quarterly earnings results on Monday. The company reported ($0.80) earnings per share for the quarter, topping analysts' consensus estimates of ($1.23) by $0.43, Zacks reports. Axsome Therapeutics had a negative return on equity of 223.51% and a negative net margin of 74.47%.

Axsome Therapeutics Trading Down 0.0 %

AXSM stock opened at $112.21 on Monday. Axsome Therapeutics has a 12-month low of $64.11 and a 12-month high of $139.13. The business's 50-day moving average is $113.58 and its 200 day moving average is $104.02. The company has a current ratio of 2.11, a quick ratio of 2.04 and a debt-to-equity ratio of 3.22. The stock has a market cap of $5.52 billion, a price-to-earnings ratio of -18.73 and a beta of 0.46.

Insider Buying and Selling at Axsome Therapeutics

In related news, CFO Nick Pizzie sold 3,000 shares of the stock in a transaction on Friday, February 14th. The stock was sold at an average price of $131.07, for a total value of $393,210.00. Following the completion of the transaction, the chief financial officer now directly owns 42,187 shares of the company's stock, valued at approximately $5,529,450.09. This represents a 6.64 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 22.40% of the company's stock.

Analyst Ratings Changes

Several research firms have weighed in on AXSM. Truist Financial boosted their price target on Axsome Therapeutics from $190.00 to $200.00 and gave the company a "buy" rating in a research note on Wednesday, February 19th. Royal Bank of Canada increased their price target on shares of Axsome Therapeutics from $190.00 to $193.00 and gave the stock an "outperform" rating in a report on Tuesday, April 29th. Cantor Fitzgerald restated an "overweight" rating and set a $153.00 price objective on shares of Axsome Therapeutics in a research note on Wednesday, February 19th. William Blair reissued an "outperform" rating on shares of Axsome Therapeutics in a report on Tuesday, February 18th. Finally, Robert W. Baird lifted their target price on shares of Axsome Therapeutics from $132.00 to $160.00 and gave the company an "outperform" rating in a report on Monday, March 3rd. One equities research analyst has rated the stock with a hold rating and sixteen have given a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $169.87.

About Axsome Therapeutics

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.